What topics does this cannabis study cover?

This study covers research on: Pain, Mental Health, Endocannabinoid, Neuroprotection.

Where was this research published?

Published in Pain on June 25, 2026.

Pain Mental Health Endocannabinoid Neuroprotection

Boosting natural cannabinoids eases both chronic pain and depression

Q: What did this research study find?

This groundbreaking study reveals how blocking the enzyme *monoacylglycerol lipase* (MGL) can simultaneously treat both chronic pain and depression—two conditions that frequently occur together. Researchers used MJN110, an *MGL inhibitor*, to boost levels of *2-arachidonoylglycerol* (2-AG), a natura

Dissociable peripheral and central mechanisms of monoacylglycerol lipase inhibition on pain- and depression-related behaviors in a rat model of neuropathic pain.

Pain • June 25, 2026 • Moderately Relevant

🤖

AI Summary

This groundbreaking study reveals how blocking the enzyme monoacylglycerol lipase (MGL) can simultaneously treat both chronic pain and depression—two conditions that frequently occur together. Researchers used MJN110, an MGL inhibitor, to boost levels of 2-arachidonoylglycerol (2-AG), a natural endocannabinoid the body produces. In rats with nerve injury mimicking human neuropathic pain, the drug demonstrated dose-dependent effects: higher doses (1-5 mg/kg) relieved physical pain symptoms by suppressing pain-signaling neurons through CB1 receptors in peripheral nerve tissue, while both high and low doses reversed depression-like behaviors such as anhedonia (loss of pleasure) and behavioral despair.

The most striking discovery involves the separation of pain and mood effects. Low-dose MJN110 restored normal brain activity in the medial prefrontal cortex (mPFC)—a region crucial for mood regulation—and reversed depression symptoms without reducing physical pain hypersensitivity. This dissociation suggests that endocannabinoid signaling operates through distinct mechanisms for the sensory and emotional dimensions of pain. The research identified that CB1 receptor activation was essential for both antidepressant and pain-relieving effects, while CB2 receptors played a minimal role in pain relief.

These findings support endocannabinoid augmentation—strategically boosting the body's natural cannabinoid system—as a promising dual-action therapy for chronic pain patients suffering from comorbid depression. Rather than a one-size-fits-all approach, the dose-specific targeting of different brain and peripheral tissues offers potential for personalized treatment strategies. This research validates the therapeutic potential of enhancing the endocannabinoid system through enzyme inhibition, particularly relevant for developing novel treatments that address both the physical and psychological burdens of chronic pain.

📄 Original Abstract

Chronic pain is a significant risk factor for depression, but mechanisms linking these conditions remain unclear. The endocannabinoid 2-arachidonoylglycerol, degraded by monoacylglycerol lipase (MGL), modulates both pain and mood. Although MGL inhibition enhances 2-arachidonoylglycerol signaling, its antidepressant potential in chronic pain has not been fully defined. We examined the behavioral, electrophysiological, and receptor-specific effects of the MGL inhibitor MJN110 in rats with spared nerve injury. Pain- and depression-like behaviors were assessed, and in vivo single-unit recordings were performed from dorsal root ganglion (DRG) neurons and medial prefrontal cortex (mPFC) pyramidal neurons. Cannabinoid receptors type 1 (CB1R) and 2 (CB2R) antagonists were used to determine receptor mechanisms. MJN110 produced dose-dependent differential effects on sensory and depression-related behaviors. Higher doses (1-5 mg/kg) alleviated mechanical and cold hypersensitivity via suppression of DRG nociceptor activity through peripheral CB1Rs. Both high (1 and 5 mg/kg) and low doses (0.3 mg/kg) reversed spared nerve injury-induced depression-like behaviors, including anhedonia and behavioral despair. Low-dose MJN110 normalized suppressed mPFC firing without altering nociceptive thresholds. CB1R blockade abolished both antidepressant and antinociceptive effects, whereas CB2R antagonism had only a minimal impact on antinociception. These findings suggest that MGL inhibition alleviates pain-induced depression potentially by restoring mPFC activity, even at doses insufficient to relieve sensory hypersensitivity. High-dose MGL inhibition reduces sensory hypersensitivity via activation of peripheral CB1Rs on DRG neurons. These findings identify dose- and site-specific CB1R mechanisms for separating the sensory and affective dimensions of pain and support endocannabinoid augmentation as a dual antidepressant-antinociceptive strategy in chronic pain comorbidity.

Paper Type

📄 Research

Publication

Journal: Pain
Published: June 25, 2026
PMID: 42350317
DOI: 10.1097/j.pain.0000000000004055

Authors (5)

Dongman Chao Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, WI, United States.
Yin Feng Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, WI, United States.
Tao Cheng Department of Neurobiology, University of Texas Medical Branch, Galveston, TX, United States.
Quinn Hogan Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, WI, United States.
Bin Pan Department of Neurobiology, University of Texas Medical Branch, Galveston, TX, United States.